|
|
Article: SangStat's Ulcerative Colitis Drug Positive In Phase II, Fails Crohn's.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
National Editor
With a new CEO installed and a recent favorable court ruling, SangStat Medical Corp. chalked up more good news Wednesday: positive preliminary Phase II data with RDP58, its drug for ulcerative colitis.
The outcome of the trial was less positive for patients with Crohn's disease, in whom no statistically significant response was shown. But the company's shares (NASDAQ:SANG) closed Wednesday at $13.33, up $2.48, or 22.9 percent.
"We're not terribly surprised," said Bill Martin, director of corporate communications for Fremont, Calif.-based SangStat, noting that the drug is not absorbed systemically and thus would more likely be ...